Baird downgraded Inari Medical (NARI) to Neutral from Outperform with a price target of $80, down from $81, after the company entered into a definitive agreement to be acquired by Stryker (SYK) for $80 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: